Munich, Germany — VeonGen Therapeutics, a clinical-stage genetic medicine company developing next-generation gene therapies, today announced clinical progress of VG801, with an oral presentation at the 2026 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held May 3-7 in Denver, Colorado. VG801, an investigational gene therapy...
Latest News
MUNICH, Germany — VeonGen Therapeutics, a clinical-stage genetic medicine company developing next-generation gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to VG801, its lead investigational gene therapy for Stargardt disease and other ABCA4 mutation–associated retinal dystrophies. By delivering a...
BRISBANE, Calif. — Vera Therapeutics, Inc., a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced positive 72-week data from the open label extension (OLE) period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN). In...
BRISBANE, Calif. — Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted TRUTAKNA (atacicept-vymj) accelerated approval to reduce proteinuria in adults with primary IgAN at risk for disease progression. In a prespecified interim analysis of the ongoing ORIGIN...
BRISBANE, Calif. — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the atacicept Biologics License Application (BLA) for the treatment of adults with immunoglobulin A nephropathy (IgAN) was accepted for Priority Review by...
BRISBANE, Calif. — Vera Therapeutics, Inc. (Nasdaq: VERA) today announced data from the ORIGIN Phase 3 trial of atacicept in IgA nephropathy (IgAN) were presented as a featured late-breaking oral presentation during the opening plenary session of the American Society of Nephrology (ASN) Kidney Week 2025 and simultaneously published in...
SOUTH SAN FRANCISCO, Calif. – Veracyte, Inc. (Nasdaq: VCYT) announced that data reinforcing the diagnostic performance and utility of the Envisia® Genomic Classifier are being shared at the American Thoracic Society (ATS) 2021 International Conference, taking place today through May 18. The company is also presenting new data which demonstrate that the...
BOSTON, Mass. — Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that it has initiated its international confirmatory Phase 3 RAMP 301 trial (GOG-3097; ENGOT-ov81/NCRI), evaluating the combination of avutometinib and defactinib versus standard chemotherapy or hormonal therapy for the treatment of...
BOSTON – Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a mini oral presentation highlighting updated data from the ongoing investigator-sponsored Phase 1/2 FRAME study. The FRAME study, led by The Institute of Cancer Research, London, and The Royal Marsden NHS...
BOSTON, Mass. — Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Verastem Oncology’s investigational RAF/MEK clamp, avutometinib, in combination with Amgen’s KRAS G12C inhibitor, LUMAKRASTM (sotorasib), for the treatment...